Because increased CRAF and IGF1R activity have each been implicated in melanoma BRAFV600E inhibitor resistance [11, 21], we examined RGC vs. corresponding TNPC for phospho- CRAF and IGF1R levels by immunoblotting. The gene discussed is RAF1; the disease is melanoma.